{"gene":"SLC18A3","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":1994,"finding":"VAChT mRNA expression uniquely co-defines the cholinergic phenotype in mammalian CNS and PNS neurons, consistent with its role in acetylcholine vesicular storage, and its distribution pattern matches known functional cholinergic neuron populations.","method":"In situ hybridization mapping of VAChT mRNA distribution in rat CNS and PNS","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single-method (ISH) but replicated across anatomical regions and consistent with functional cholinergic anatomy","pmids":["7857778"],"is_preprint":false},{"year":1997,"finding":"VAChT protein localizes to synaptic vesicles within cholinergic nerve terminals (granular staining in cell bodies, axon terminals, and dendrites), and is distinct from vesicular monoamine transporter (VMAT); VAChT and ChAT co-localize in the same cholinergic neurons.","method":"Immunohistochemistry with specific polyclonal antisera (validated by absorption controls and transfection in CV-1 cells), confocal laser microscopy, and double-labeling with ChAT","journal":"The Journal of comparative neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — specific antisera validated in transfected cells, absorption controls, double-labeling, replicated across multiple CNS and PNS regions","pmids":["9034903"],"is_preprint":false},{"year":1998,"finding":"The VAChT gene is located within the first intron of the ChAT gene and is in the same transcriptional orientation, forming a single 'cholinergic gene locus' (CGL); both genes share promoter regulatory elements, suggesting coordinate regulation.","method":"Genomic cloning and structural analysis of the cholinergic locus","journal":"Journal of physiology, Paris","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genomic structural analysis, single report but consistent with transfection assay data in related papers","pmids":["9782459"],"is_preprint":false},{"year":2000,"finding":"A repressor element 1/neuron-restrictive silencer element (RE1/NRSE) located in the 2336-bp region upstream of the ChAT and VAChT coding sequences silences VAChT promoter activity in non-neuronal cells but not in neuronal cells; RE1-silencing transcription factor (REST/NRSF) and several other proteins are recruited to this regulatory sequence, suggesting coordinate repression of ChAT and VAChT in non-cholinergic cells.","method":"Transfection assays with luciferase reporter constructs, electrophoretic mobility shift assay (EMSA) for protein-DNA interactions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — transfection reporter assays plus protein-DNA binding demonstrated in a single focused study with multiple orthogonal methods","pmids":["10973977"],"is_preprint":false},{"year":2002,"finding":"VAChT overexpression in PC12 cells increases ATP-dependent, vesamicol-inhibitable [3H]ACh accumulation in membrane fractions by ~2.5-fold, demonstrating VAChT directly mediates vesicular ACh uptake; however, overexpression does not augment uptake of newly synthesized [14C]ACh into vesicles, indicating vesicular ACh release from PC12 cells is not rate-limited by VAChT levels.","method":"Stable transfection of rat VAChT cDNA into PC12 cells; [3H]vesamicol binding; [3H]ACh and [14C]ACh vesicular uptake assays; Western blot","journal":"Brain research. Molecular brain research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro vesicular transport reconstitution in transfected cells with pharmacological inhibition (vesamicol), multiple assay methods in one study","pmids":["12008018"],"is_preprint":false},{"year":2003,"finding":"PKA signaling plays a major role in regulating both ChAT and VAChT mRNA levels in NG108-15 cells (H89, a PKA inhibitor, decreased both); PI3K inhibition (LY294002) had opposite effects on the two genes — decreasing ChAT mRNA while increasing VAChT mRNA — demonstrating that ChAT and VAChT can be differentially regulated despite their shared locus.","method":"Pharmacological inhibition of signaling kinases (H89, LY294002, PD98059) in NG108-15 cells; RT-PCR for mRNA levels; ChAT activity assays","journal":"Neurochemical research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors tested with mRNA and activity readouts in a single lab study","pmids":["12675145"],"is_preprint":false},{"year":2003,"finding":"VAChT mRNA and protein upregulation with differentiating agents (retinoic acid, dexamethasone, dbcAMP) in NG108-15 cells does not always translate to increased VAChT protein, indicating post-transcriptional or post-translational regulation including deficient complex glycosylation that may affect targeting and/or stability of the VAChT membrane protein.","method":"RT-PCR, Western blot, ligand binding assays, transfection with luciferase reporter, glycosylation analysis in NG108-15 cells","journal":"Journal of physiology, Paris","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (mRNA, protein, binding, reporter) but single-lab study","pmids":["11755784"],"is_preprint":false},{"year":2006,"finding":"In C. elegans, an unc-17/VAChT missense mutation (G347R in transmembrane domain 9) causing uncoordinated behavior is suppressed by a synaptobrevin/SNB-1 transmembrane domain mutation (I→D), suggesting a physical or functional association between VAChT and SNARE components at synaptic vesicles.","method":"Genetic epistasis/suppressor screen in C. elegans; behavioral analysis of double mutants","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis with allele-specific suppression, published in high-tier journal, mechanism-specific result","pmids":["16604067"],"is_preprint":false},{"year":2012,"finding":"In C. elegans, the transmembrane protein SUP-1 physically associates with UNC-17/VAChT at synapses (demonstrated by bimolecular fluorescence complementation), and charge-complementary mutations in the transmembrane domains of SUP-1 (G84E) suppress the uncoordinated phenotype of UNC-17(G347R), suggesting electrostatic interactions between transmembrane domains modulate VAChT conformation and function.","method":"Genetic suppressor screen, bimolecular fluorescence complementation (BiFC), behavioral analysis in C. elegans","journal":"Genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — BiFC proximity assay plus allele-specific genetic suppression, two orthogonal methods in one study","pmids":["23051648"],"is_preprint":false},{"year":2013,"finding":"Overexpression of the transcription factor Lhx8 in SHSY5Y neuronal cells upregulates both ChAT and VAChT mRNA/protein expression and increases ACh release into culture medium, placing Lhx8 upstream of VAChT in the transcriptional control of cholinergic phenotype.","method":"Lentiviral Lhx8 overexpression in SHSY5Y cells; RT-PCR, Western blot, ACh release measurement","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — gain-of-function with mRNA, protein, and functional (ACh release) readouts, but single lab, single condition","pmids":["24316404"],"is_preprint":false},{"year":2014,"finding":"BAC transgenic mice overexpressing VAChT (with ~50 extra copies) show striatal VAChT protein overexpression and increased ACh release, leading to markedly enhanced amphetamine-induced stereotypies (confined sniffing and licking), demonstrating that VAChT-mediated increases in cholinergic tone directly exacerbate drug-induced repetitive behaviors.","method":"VAChT BAC transgenic mouse model; behavioral testing (amphetamine-induced stereotypy scoring); Western blot for striatal VAChT protein","journal":"Frontiers in neural circuits","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression with protein quantification and defined behavioral phenotype, replicated in Janickova et al. 2017","pmids":["24904300"],"is_preprint":false},{"year":2016,"finding":"Biallelic loss-of-function variants in SLC18A3 (VAChT) cause presynaptic congenital myasthenic syndrome in humans, characterized by ptosis, ophthalmoplegia, fatigable weakness, apneic crises, and electrodecrement on repetitive stimulation — consistent with impaired ACh loading into presynaptic vesicles at the neuromuscular junction.","method":"Whole-exome sequencing; electrophysiological studies (repetitive nerve stimulation); clinical phenotyping","journal":"Neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetic loss-of-function validated by electrophysiology consistent with presynaptic mechanism, replicated across two unrelated families","pmids":["27590285"],"is_preprint":false},{"year":2017,"finding":"VAChT overexpression in striatal cholinergic interneurons (ChAT-ChR2 BAC mice) dramatically reduces the number of cholinergic varicosities (−87%) while increasing their size (+177%) and alters VAChT trafficking along the somatodendritic and axonal arbor, demonstrating that VAChT expression levels regulate the morphology and intracellular trafficking of cholinergic terminals.","method":"Immunofluorescence quantification of VAChT-positive varicosities in transgenic mouse striatum; confocal microscopy; morphometric analysis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined morphological readout in genetic model with quantitative analysis, single lab","pmids":["28628197"],"is_preprint":false},{"year":2018,"finding":"Mice with ~65% knockdown of VAChT (VAChT-KDHOM) show reduced ACh release at neuromuscular junctions, causing muscle weakness with differential effects: fast-twitch EDL fibers atrophy while slow-twitch soleus fibers hypertrophy; altered expression of myogenesis markers (Pax7, MyoD, Myogenin), metabolic markers (PGC1-α), and protein degradation markers (Atrogin1, MuRF1) indicates distinct muscle adaptation to cholinergic deficits. These deficits are partially reversed by pyridostigmine.","method":"VAChT knockdown mouse model; muscle histology and morphometry; qRT-PCR for muscle-related genes; pyridostigmine pharmacological rescue","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with molecular and cellular phenotypic readouts plus pharmacological rescue, single lab","pmids":["30003945"],"is_preprint":false},{"year":2019,"finding":"A homozygous nonsense variant in SLC18A3 [p.(Cys372Ter)] causes fetal akinesia deformation sequence (FADS) with arthrogryposis and edema, extending the disease spectrum beyond congenital myasthenic syndrome and suggesting complete loss of VAChT function is lethal prenatally — consistent with VAChT knockout mouse lethality.","method":"Exome sequencing; clinical and pathological phenotyping of affected fetuses","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — human genetics establishing null-allele phenotype, consistent with mouse knockout, but single family","pmids":["31059209"],"is_preprint":false},{"year":2021,"finding":"Motoneuron-specific deletion of VAChT (Cre-loxP, mnVAChT-KD) in mice causes reduced ACh release, motoneuron soma shrinkage, innervated muscle atrophy, decreased muscle strength, hypoactivity, and kyphosis that worsen progressively — deficits partially rescued by cholinesterase inhibitor — establishing cell-autonomous requirement for VAChT in motoneuron function and neuromuscular junction integrity.","method":"Cre-loxP conditional knockout in motoneurons; immunofluorescence; muscle histology; grip strength and behavioral testing; pyridostigmine pharmacological rescue","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional genetic loss-of-function with multiple orthogonal cellular and behavioral readouts plus pharmacological rescue in single rigorous study","pmids":["33730374"],"is_preprint":false},{"year":2022,"finding":"SLC18A3/VAChT overexpression in renal cancer cells enhances uptake of acetylcholine, which activates the PKA/CREB signaling pathway to promote cell proliferation and invasive migration; SLC18A3 overexpression in mice bearing A498 renal cancer cells increases tumor growth and lung metastases.","method":"SLC18A3 overexpression in renal cancer cell lines; ACh uptake assays; PKA/CREB pathway analysis; xenograft mouse tumor model","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in vitro and in vivo with defined signaling pathway readouts, single lab","pmids":["36225635"],"is_preprint":false},{"year":2025,"finding":"In cognitively normal older adults at risk for Alzheimer's disease, cholinergic neurons increase presynaptic VAChT protein levels when co-localized with tau (but not amyloid) pathology, and stronger VAChT responses are associated with cognitive resilience over a decade; forebrain-specific VAChT deletion in mice impairs cortical plasticity and hippocampal structural integrity, demonstrating VAChT-dependent cholinergic synaptic plasticity as a mechanism of resilience to tau pathology.","method":"Multi-tracer PET imaging in humans; forebrain-specific conditional VAChT knockout in mice; single-nucleus RNA sequencing; structural MRI","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — convergent human PET and mouse genetic KO with multiple orthogonal methods; preprint not yet peer-reviewed","pmids":[],"is_preprint":true}],"current_model":"SLC18A3/VAChT is an integral membrane transporter located on synaptic vesicles of cholinergic neurons that actively loads acetylcholine into vesicles via an ATP-dependent, vesamicol-inhibitable mechanism; its gene resides within the first intron of ChAT and is co-regulated through shared RE1/NRSE silencer elements and PKA/PI3K signaling pathways; VAChT physically associates with SNARE components (synaptobrevin) and the transmembrane protein SUP-1 via transmembrane domain interactions that modulate its conformation and function; VAChT expression levels directly control the quantity of ACh available for release, with loss-of-function causing presynaptic congenital myasthenic syndrome or fetal akinesia in humans, and gain-of-function increasing cholinergic tone with consequences for striatal morphology, drug-induced behaviors, and cognitive resilience to tau pathology."},"narrative":{"mechanistic_narrative":"SLC18A3 (VAChT) is the vesicular acetylcholine transporter that defines the cholinergic phenotype of CNS and PNS neurons and loads acetylcholine into synaptic vesicles for release [PMID:7857778, PMID:9034903]. It localizes to synaptic vesicles in cholinergic nerve terminals, cell bodies, and dendrites, where it co-localizes with the ACh-synthesizing enzyme ChAT [PMID:9034903], and it directly mediates ATP-dependent, vesamicol-inhibitable vesicular ACh uptake [PMID:12008018]. The VAChT gene resides within the first intron of ChAT in a shared 'cholinergic gene locus' that permits coordinate transcriptional control through a common RE1/NRSE silencer engaged by REST/NRSF in non-neuronal cells [PMID:9782459, PMID:10973977], while PKA and PI3K signaling and upstream factors such as Lhx8 tune cholinergic gene output [PMID:12675145, PMID:24316404]. At the vesicle membrane VAChT functions in proximity to the SNARE protein synaptobrevin and the transmembrane protein SUP-1, whose transmembrane-domain interactions modulate VAChT conformation and activity [PMID:16604067, PMID:23051648]. VAChT expression levels set the quantity of releasable ACh and thereby govern neuromuscular and central cholinergic tone: biallelic loss-of-function variants cause presynaptic congenital myasthenic syndrome, and a null variant causes lethal fetal akinesia deformation sequence [PMID:27590285, PMID:31059209], whereas reduced or motoneuron-specific deletion produces neuromuscular junction failure, muscle atrophy, and weakness that is partially reversed by cholinesterase inhibition [PMID:30003945, PMID:33730374]. Conversely, VAChT overexpression raises cholinergic tone, remodels striatal cholinergic terminal morphology, and exacerbates drug-induced stereotypies [PMID:24904300, PMID:28628197].","teleology":[{"year":1994,"claim":"Establishing that a single transporter transcript marks cholinergic neurons answered whether ACh vesicular storage has a dedicated, cell-type-defining carrier.","evidence":"In situ hybridization mapping of VAChT mRNA across rat CNS and PNS","pmids":["7857778"],"confidence":"Medium","gaps":["mRNA distribution does not demonstrate transport activity","subcellular localization not resolved by ISH"]},{"year":1997,"claim":"Localizing VAChT protein to synaptic vesicles and confirming co-expression with ChAT established its position in the ACh release pathway.","evidence":"Immunohistochemistry with validated antisera, confocal microscopy, double-labeling with ChAT","pmids":["9034903"],"confidence":"High","gaps":["does not quantify transport function","does not address regulation of expression"]},{"year":1998,"claim":"Mapping VAChT inside the first intron of ChAT revealed a shared cholinergic gene locus, framing how the two cholinergic genes might be co-regulated.","evidence":"Genomic cloning and structural analysis of the cholinergic locus","pmids":["9782459"],"confidence":"Medium","gaps":["functional consequence of shared locus not tested in this report","regulatory elements not yet identified"]},{"year":2000,"claim":"Identifying an RE1/NRSE silencer bound by REST/NRSF explained how VAChT (and ChAT) are repressed in non-cholinergic cells, providing a molecular basis for coordinate cell-type-specific expression.","evidence":"Luciferase reporter transfection and EMSA for protein-DNA binding","pmids":["10973977"],"confidence":"High","gaps":["additional bound proteins beyond REST not fully defined","in vivo requirement of the element not tested"]},{"year":2002,"claim":"Demonstrating that VAChT overexpression increases ATP-dependent, vesamicol-inhibitable ACh uptake confirmed VAChT as the direct mediator of vesicular ACh loading, while showing VAChT is not always the rate-limiting step for release.","evidence":"Stable VAChT transfection in PC12 cells with vesicular [3H]ACh/[14C]ACh uptake and vesamicol binding assays","pmids":["12008018"],"confidence":"High","gaps":["mechanism of transport coupling not resolved","rate-limiting determinants of release not identified"]},{"year":2003,"claim":"Showing PKA and PI3K differentially regulate ChAT versus VAChT mRNA, and that differentiating agents act post-transcriptionally including via glycosylation, established that co-locus genes are nonetheless independently tunable and that VAChT protein levels are controlled beyond transcription.","evidence":"Kinase inhibitor pharmacology, RT-PCR, Western blot, and glycosylation analysis in NG108-15 cells","pmids":["12675145","11755784"],"confidence":"Medium","gaps":["signaling-to-promoter mechanism not mapped","glycosylation effect on trafficking not directly demonstrated"]},{"year":2006,"claim":"Allele-specific suppression of an unc-17/VAChT transmembrane mutation by a synaptobrevin mutation provided genetic evidence for a functional association between VAChT and SNARE machinery at the vesicle.","evidence":"Genetic epistasis/suppressor screen and behavioral analysis in C. elegans","pmids":["16604067"],"confidence":"High","gaps":["physical interaction not shown biochemically","interaction not confirmed in mammalian neurons"]},{"year":2012,"claim":"Demonstrating physical proximity of SUP-1 to UNC-17/VAChT and charge-complementary transmembrane suppression revealed that transmembrane-domain electrostatic interactions modulate VAChT conformation and function.","evidence":"BiFC proximity assay and allele-specific genetic suppression in C. elegans","pmids":["23051648"],"confidence":"High","gaps":["mammalian SUP-1 ortholog and conservation not established","structural basis of conformational modulation unresolved"]},{"year":2013,"claim":"Placing Lhx8 upstream of VAChT in transcriptional control identified a transcription factor driving the cholinergic phenotype and ACh release.","evidence":"Lentiviral Lhx8 overexpression in SHSY5Y cells with RT-PCR, Western blot, and ACh release measurement","pmids":["24316404"],"confidence":"Medium","gaps":["direct promoter binding by Lhx8 not demonstrated","single cell-line, single condition"]},{"year":2017,"claim":"Gain-of-function studies linked VAChT levels to cholinergic tone and behavior, showing overexpression increases ACh release, drives amphetamine-induced stereotypies, and remodels striatal terminal morphology and trafficking.","evidence":"VAChT BAC transgenic and ChAT-ChR2 mice with behavioral scoring, Western blot, and varicosity morphometry","pmids":["24904300","28628197"],"confidence":"Medium","gaps":["mechanism linking VAChT level to varicosity remodeling unresolved","circuit-level cause of behavioral change not dissected"]},{"year":2016,"claim":"Identifying biallelic loss-of-function variants in human SLC18A3 established VAChT deficiency as a cause of presynaptic congenital myasthenic syndrome, confirming its physiological requirement for ACh loading at the neuromuscular junction.","evidence":"Whole-exome sequencing, repetitive nerve stimulation electrophysiology, and clinical phenotyping across families","pmids":["27590285"],"confidence":"High","gaps":["genotype-phenotype severity correlation not fully mapped","molecular consequence of specific variants not assayed"]},{"year":2019,"claim":"A homozygous nonsense variant causing fetal akinesia extended the phenotypic spectrum and indicated that complete VAChT loss is prenatally lethal, consistent with knockout mouse lethality.","evidence":"Exome sequencing and clinical/pathological phenotyping of affected fetuses","pmids":["31059209"],"confidence":"Medium","gaps":["single family","residual transporter function of hypomorphic alleles not quantified"]},{"year":2021,"claim":"Quantitative loss-of-function and motoneuron-specific deletion established a cell-autonomous requirement for VAChT in neuromuscular junction integrity, with distinct fast- versus slow-twitch muscle adaptations and partial pharmacological rescue.","evidence":"VAChT knockdown and Cre-loxP conditional motoneuron knockout mice with histology, qRT-PCR, behavior, and pyridostigmine rescue","pmids":["30003945","33730374"],"confidence":"High","gaps":["fiber-type-specific adaptation mechanism not fully defined","long-term reversibility of deficits unresolved"]},{"year":2022,"claim":"Showing VAChT-driven ACh uptake activates PKA/CREB to promote proliferation and metastasis implicated SLC18A3 in non-neuronal cholinergic signaling in renal cancer.","evidence":"SLC18A3 overexpression in renal cancer cells with ACh uptake assays, pathway analysis, and xenograft tumor model","pmids":["36225635"],"confidence":"Medium","gaps":["endogenous SLC18A3 dependence in tumors not tested by loss-of-function","source of ACh in tumor context unclear"]},{"year":2025,"claim":"Convergent human PET and mouse genetic data tied VAChT-dependent presynaptic plasticity to cognitive resilience against tau pathology, framing cholinergic capacity as a protective mechanism.","evidence":"Multi-tracer PET in older adults, forebrain-specific conditional VAChT knockout mice, snRNA-seq, and structural MRI (preprint)","pmids":[],"confidence":"Medium","gaps":["preprint not yet peer-reviewed","causal direction between VAChT upregulation and resilience not established in humans","molecular trigger for tau-associated VAChT increase unknown"]},{"year":null,"claim":"The atomic structure of VAChT and the transport/coupling mechanism by which it loads ACh into vesicles remain undefined in the available corpus.","evidence":"No structural or reconstituted mechanistic study present in the timeline","pmids":[],"confidence":"Low","gaps":["no high-resolution structure","ion/proton coupling stoichiometry not characterized","vesamicol binding site not mapped structurally"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[4,0,1]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,1,4]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,2]}],"complexes":[],"partners":["SNB-1","SUP-1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16572","full_name":"Vesicular acetylcholine transporter","aliases":["Solute carrier family 18 member 3"],"length_aa":532,"mass_kda":56.9,"function":"Electrogenic antiporter that exchanges one cholinergic neurotransmitter, acetylcholine or choline, with two intravesicular protons across the membrane of synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to store neurotransmitters inside the vesicles prior to their release via exocytosis (By similarity) (PubMed:20225888, PubMed:8910293). Determines cholinergic vesicular quantal size at presynaptic nerve terminals in developing neuro-muscular junctions with an impact on motor neuron differentiation and innervation pattern (By similarity). Part of forebrain cholinergic system, regulates hippocampal synapse transmissions that underlie spatial memory formation (By similarity). Can transport serotonin","subcellular_location":"Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane","url":"https://www.uniprot.org/uniprotkb/Q16572/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC18A3","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC18A3","total_profiled":1310},"omim":[{"mim_id":"617239","title":"MYASTHENIC SYNDROME, CONGENITAL, 21, PRESYNAPTIC; CMS21","url":"https://www.omim.org/entry/617239"},{"mim_id":"601462","title":"MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A","url":"https://www.omim.org/entry/601462"},{"mim_id":"600336","title":"SOLUTE CARRIER FAMILY 18 (VESICULAR ACETYLCHOLINE), MEMBER 3; SLC18A3","url":"https://www.omim.org/entry/600336"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":5.2}],"url":"https://www.proteinatlas.org/search/SLC18A3"},"hgnc":{"alias_symbol":["VACHT"],"prev_symbol":[]},"alphafold":{"accession":"Q16572","domains":[{"cath_id":"1.20.1250.20","chopping":"21-64_118-277","consensus_level":"medium","plddt":86.2025,"start":21,"end":277},{"cath_id":"1.20.1250.20","chopping":"279-477","consensus_level":"medium","plddt":90.1649,"start":279,"end":477}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16572","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16572-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16572-F1-predicted_aligned_error_v6.png","plddt_mean":76.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC18A3","jax_strain_url":"https://www.jax.org/strain/search?query=SLC18A3"},"sequence":{"accession":"Q16572","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16572.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16572/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16572"}},"corpus_meta":[{"pmid":"9034903","id":"PMC_9034903","title":"Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems.","date":"1997","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9034903","citation_count":355,"is_preprint":false},{"pmid":"7857778","id":"PMC_7857778","title":"Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat.","date":"1994","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/7857778","citation_count":96,"is_preprint":false},{"pmid":"8860234","id":"PMC_8860234","title":"Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter.","date":"1995","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/8860234","citation_count":77,"is_preprint":false},{"pmid":"27590285","id":"PMC_27590285","title":"Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27590285","citation_count":51,"is_preprint":false},{"pmid":"10421869","id":"PMC_10421869","title":"Differential expression of nerve terminal protein isoforms in VAChT-containing varicosities of the spinal cord ventral horn.","date":"1999","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10421869","citation_count":48,"is_preprint":false},{"pmid":"24904300","id":"PMC_24904300","title":"Severe drug-induced repetitive behaviors and striatal overexpression of VAChT in ChAT-ChR2-EYFP BAC transgenic mice.","date":"2014","source":"Frontiers in neural circuits","url":"https://pubmed.ncbi.nlm.nih.gov/24904300","citation_count":48,"is_preprint":false},{"pmid":"21948486","id":"PMC_21948486","title":"Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21948486","citation_count":45,"is_preprint":false},{"pmid":"16572456","id":"PMC_16572456","title":"Vesicular glutamate (VGlut), GABA (VGAT), and acetylcholine (VACht) transporters in basal forebrain axon terminals innervating the lateral hypothalamus.","date":"2006","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16572456","citation_count":44,"is_preprint":false},{"pmid":"20583990","id":"PMC_20583990","title":"PET radioligands for the vesicular acetylcholine transporter (VAChT).","date":"2010","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20583990","citation_count":39,"is_preprint":false},{"pmid":"14502577","id":"PMC_14502577","title":"VAChT-Cre. Fast and VAChT-Cre.Slow: postnatal expression of Cre recombinase in somatomotor neurons with different onset.","date":"2003","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/14502577","citation_count":31,"is_preprint":false},{"pmid":"21742018","id":"PMC_21742018","title":"Co-expression studies of the orphan carrier protein Slc10a4 and the vesicular carriers VAChT and VMAT2 in the rat central and peripheral nervous system.","date":"2011","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21742018","citation_count":31,"is_preprint":false},{"pmid":"9376516","id":"PMC_9376516","title":"Vesicular acetylcholine transporter (VAChT): a cellular marker in rat retinal development.","date":"1997","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/9376516","citation_count":31,"is_preprint":false},{"pmid":"9782459","id":"PMC_9782459","title":"The cholinergic locus: ChAT and VAChT genes.","date":"1998","source":"Journal of physiology, Paris","url":"https://pubmed.ncbi.nlm.nih.gov/9782459","citation_count":29,"is_preprint":false},{"pmid":"33940317","id":"PMC_33940317","title":"Expression of VAChT and 5-HT in Ulcerative colitis dendritic cells.","date":"2021","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/33940317","citation_count":26,"is_preprint":false},{"pmid":"16604067","id":"PMC_16604067","title":"A genetic interaction between the vesicular acetylcholine transporter VAChT/UNC-17 and synaptobrevin/SNB-1 in C. elegans.","date":"2006","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16604067","citation_count":26,"is_preprint":false},{"pmid":"11755784","id":"PMC_11755784","title":"More than one way to toy with ChAT and VAChT.","date":"2002","source":"Journal of physiology, Paris","url":"https://pubmed.ncbi.nlm.nih.gov/11755784","citation_count":24,"is_preprint":false},{"pmid":"11306187","id":"PMC_11306187","title":"Stimuli that induce a cholinergic neuronal phenotype of NG108-15 cells upregulate ChAT and VAChT mRNAs but fail to increase VAChT protein.","date":"2001","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/11306187","citation_count":24,"is_preprint":false},{"pmid":"9568566","id":"PMC_9568566","title":"Innervation of intestinal arteries by axons with immunoreactivity for the vesicular acetylcholine transporter (VAChT).","date":"1998","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/9568566","citation_count":24,"is_preprint":false},{"pmid":"12675145","id":"PMC_12675145","title":"Exploring the regulation of the expression of ChAT and VAChT genes in NG108-15 cells: implication of PKA and PI3K signaling pathways.","date":"2003","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/12675145","citation_count":23,"is_preprint":false},{"pmid":"28628197","id":"PMC_28628197","title":"Vesicular acetylcholine transporter (VAChT) over-expression induces major modifications of striatal cholinergic interneuron morphology and function.","date":"2017","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28628197","citation_count":21,"is_preprint":false},{"pmid":"10704834","id":"PMC_10704834","title":"The early expression of VAChT and VIP in mouse sympathetic ganglia is not induced by cytokines acting through LIFRbeta or CNTFRalpha.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10704834","citation_count":20,"is_preprint":false},{"pmid":"22615654","id":"PMC_22615654","title":"Effects of training in the Morris water maze on the spatial learning acquisition and VAChT expression in male rats.","date":"2011","source":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22615654","citation_count":20,"is_preprint":false},{"pmid":"32619677","id":"PMC_32619677","title":"Effects of VAChT reduction and α7nAChR stimulation by PNU-282987 in lung inflammation in a model of chronic allergic airway inflammation.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32619677","citation_count":19,"is_preprint":false},{"pmid":"10973977","id":"PMC_10973977","title":"Is RE1/NRSE a common cis-regulatory sequence for ChAT and VAChT genes?","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10973977","citation_count":18,"is_preprint":false},{"pmid":"21401875","id":"PMC_21401875","title":"VAChT knock-down mice show normal prepulse inhibition but disrupted long-term habituation.","date":"2011","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/21401875","citation_count":16,"is_preprint":false},{"pmid":"29130637","id":"PMC_29130637","title":"How chromosomal deletions can unmask recessive mutations? Deletions in 10q11.2 associated with CHAT or SLC18A3 mutations lead to congenital myasthenic syndrome.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/29130637","citation_count":16,"is_preprint":false},{"pmid":"10375380","id":"PMC_10375380","title":"Multistratified expression of polysialic acid and its relationship to VAChT-containing neurons in the inner plexiform layer of adult rat retina.","date":"1999","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/10375380","citation_count":13,"is_preprint":false},{"pmid":"20490865","id":"PMC_20490865","title":"Immunoreactivity for high-affinity choline transporter colocalises with VAChT in human enteric nervous system.","date":"2010","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/20490865","citation_count":13,"is_preprint":false},{"pmid":"26872437","id":"PMC_26872437","title":"Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates.","date":"2015","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/26872437","citation_count":12,"is_preprint":false},{"pmid":"30003945","id":"PMC_30003945","title":"Fast and slow-twitching muscles are differentially affected by reduced cholinergic transmission in mice deficient for VAChT: A mouse model for congenital myasthenia.","date":"2018","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/30003945","citation_count":12,"is_preprint":false},{"pmid":"12008018","id":"PMC_12008018","title":"Analysis of uptake and release of newly synthesized acetylcholine in PC12 cells overexpressing the rat vesicular acetylcholine transporter (VAChT).","date":"2002","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/12008018","citation_count":12,"is_preprint":false},{"pmid":"36225635","id":"PMC_36225635","title":"SLC18A3 promoted renal cancer development through acetylcholine/cAMP signaling.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36225635","citation_count":11,"is_preprint":false},{"pmid":"23051648","id":"PMC_23051648","title":"Genetic interactions between UNC-17/VAChT and a novel transmembrane protein in Caenorhabditis elegans.","date":"2012","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23051648","citation_count":11,"is_preprint":false},{"pmid":"22831799","id":"PMC_22831799","title":"Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT).","date":"2012","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22831799","citation_count":11,"is_preprint":false},{"pmid":"31059209","id":"PMC_31059209","title":"SLC18A3 variants lead to fetal akinesia deformation sequence early in pregnancy.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31059209","citation_count":10,"is_preprint":false},{"pmid":"33730374","id":"PMC_33730374","title":"Motoneuron-specific loss of VAChT mimics neuromuscular defects seen in congenital myasthenic syndrome.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/33730374","citation_count":10,"is_preprint":false},{"pmid":"33090291","id":"PMC_33090291","title":"Evidence for the cholinergic markers ChAT and vAChT in sensory cells of the developing antennal nervous system of the desert locust Schistocerca gregaria.","date":"2020","source":"Invertebrate neuroscience : IN","url":"https://pubmed.ncbi.nlm.nih.gov/33090291","citation_count":9,"is_preprint":false},{"pmid":"27524473","id":"PMC_27524473","title":"Reduced expression of VAChT increases renal fibrosis.","date":"2016","source":"Pathophysiology : the official journal of the International Society for Pathophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/27524473","citation_count":8,"is_preprint":false},{"pmid":"27596971","id":"PMC_27596971","title":"Reappraisal of VAChT-Cre: Preference in slow motor neurons innervating type I or IIa muscle fibers.","date":"2016","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/27596971","citation_count":8,"is_preprint":false},{"pmid":"31767639","id":"PMC_31767639","title":"Demonstration of a Simple Epitope Tag Multimerization Strategy for Enhancing the Sensitivity of Protein Detection Using Drosophila vAChT.","date":"2020","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31767639","citation_count":8,"is_preprint":false},{"pmid":"24316404","id":"PMC_24316404","title":"Upregulation of Lhx8 increase VAChT expression and ACh release in neuronal cell line SHSY5Y.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/24316404","citation_count":7,"is_preprint":false},{"pmid":"36359371","id":"PMC_36359371","title":"BDNF Spinal Overexpression after Spinal Cord Injury Partially Protects Soleus Neuromuscular Junction from Disintegration, Increasing VAChT and AChE Transcripts in Soleus but Not Tibialis Anterior Motoneurons.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36359371","citation_count":7,"is_preprint":false},{"pmid":"25770047","id":"PMC_25770047","title":"Comparative analyses of the cholinergic locus of ChAT and VAChT and its expression in the silkworm Bombyx mori.","date":"2015","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25770047","citation_count":6,"is_preprint":false},{"pmid":"37035236","id":"PMC_37035236","title":"Computational modeling of PET imaging agents for vesicular acetylcholine transporter (VAChT) protein binding affinity: application of 2D-QSAR modeling and molecular docking techniques.","date":"2023","source":"In silico pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37035236","citation_count":5,"is_preprint":false},{"pmid":"33715111","id":"PMC_33715111","title":"Lung Edema and Mortality Induced by Intestinal Ischemia and Reperfusion Is Regulated by VAChT Levels in Female Mice.","date":"2021","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33715111","citation_count":3,"is_preprint":false},{"pmid":"22365760","id":"PMC_22365760","title":"Pyrrolovesamicols--synthesis, structure and VAChT binding of two 4-fluorobenzoyl regioisomers.","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22365760","citation_count":3,"is_preprint":false},{"pmid":"38961398","id":"PMC_38961398","title":"Effect of VAChT reduction on lung alterations induced by exposure to iron particles in an asthma model.","date":"2024","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38961398","citation_count":0,"is_preprint":false},{"pmid":"41919890","id":"PMC_41919890","title":"Targeting IL-17/NF-κB/VAChT/Rho-kinase signaling and oxidative stress in exacerbated chronic allergic inflammation: functional and therapeutic implications of IL-17 blockade.","date":"2026","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/41919890","citation_count":0,"is_preprint":false},{"pmid":"42088569","id":"PMC_42088569","title":"Absolute Configuration and an Improved Automated cGMP Production of a Clinically Promising Radiotracer for Imaging VAChT.","date":"2025","source":"Journal of fluorine chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/42088569","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.22.684048","title":"Genomic signatures associated with convergent funnel-web building behavior in spiders","date":"2025-10-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.22.684048","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.24.661373","title":"Spatial transcriptomic profiling of human paravertebral sympathetic chain ganglia reveals diabetes-induced neuroplasticity","date":"2025-06-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.24.661373","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.27.656174","title":"Cholinergic synaptic plasticity shapes resilience and vulnerability to tau","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.27.656174","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.16.682741","title":"Kölliker-Fuse/parabrachial complex PACAP - glutamate pathway to the extended amygdala couples rapid autonomic and delayed endocrine responses to acute hypotension","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682741","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.03.647119","title":"Multi-transmitter  <i>high-fidelity</i>  innervation of the forebrain extended amygdala by pontine PACAP-expressing neurons","date":"2025-04-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.03.647119","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.20.24315801","title":"Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes","date":"2024-10-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.20.24315801","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30810,"output_tokens":4490,"usd":0.07989,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12628,"output_tokens":4360,"usd":0.08607,"stage2_stop_reason":"end_turn"},"total_usd":0.16596,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"VAChT mRNA expression uniquely co-defines the cholinergic phenotype in mammalian CNS and PNS neurons, consistent with its role in acetylcholine vesicular storage, and its distribution pattern matches known functional cholinergic neuron populations.\",\n      \"method\": \"In situ hybridization mapping of VAChT mRNA distribution in rat CNS and PNS\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single-method (ISH) but replicated across anatomical regions and consistent with functional cholinergic anatomy\",\n      \"pmids\": [\"7857778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"VAChT protein localizes to synaptic vesicles within cholinergic nerve terminals (granular staining in cell bodies, axon terminals, and dendrites), and is distinct from vesicular monoamine transporter (VMAT); VAChT and ChAT co-localize in the same cholinergic neurons.\",\n      \"method\": \"Immunohistochemistry with specific polyclonal antisera (validated by absorption controls and transfection in CV-1 cells), confocal laser microscopy, and double-labeling with ChAT\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — specific antisera validated in transfected cells, absorption controls, double-labeling, replicated across multiple CNS and PNS regions\",\n      \"pmids\": [\"9034903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The VAChT gene is located within the first intron of the ChAT gene and is in the same transcriptional orientation, forming a single 'cholinergic gene locus' (CGL); both genes share promoter regulatory elements, suggesting coordinate regulation.\",\n      \"method\": \"Genomic cloning and structural analysis of the cholinergic locus\",\n      \"journal\": \"Journal of physiology, Paris\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genomic structural analysis, single report but consistent with transfection assay data in related papers\",\n      \"pmids\": [\"9782459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A repressor element 1/neuron-restrictive silencer element (RE1/NRSE) located in the 2336-bp region upstream of the ChAT and VAChT coding sequences silences VAChT promoter activity in non-neuronal cells but not in neuronal cells; RE1-silencing transcription factor (REST/NRSF) and several other proteins are recruited to this regulatory sequence, suggesting coordinate repression of ChAT and VAChT in non-cholinergic cells.\",\n      \"method\": \"Transfection assays with luciferase reporter constructs, electrophoretic mobility shift assay (EMSA) for protein-DNA interactions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — transfection reporter assays plus protein-DNA binding demonstrated in a single focused study with multiple orthogonal methods\",\n      \"pmids\": [\"10973977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"VAChT overexpression in PC12 cells increases ATP-dependent, vesamicol-inhibitable [3H]ACh accumulation in membrane fractions by ~2.5-fold, demonstrating VAChT directly mediates vesicular ACh uptake; however, overexpression does not augment uptake of newly synthesized [14C]ACh into vesicles, indicating vesicular ACh release from PC12 cells is not rate-limited by VAChT levels.\",\n      \"method\": \"Stable transfection of rat VAChT cDNA into PC12 cells; [3H]vesamicol binding; [3H]ACh and [14C]ACh vesicular uptake assays; Western blot\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro vesicular transport reconstitution in transfected cells with pharmacological inhibition (vesamicol), multiple assay methods in one study\",\n      \"pmids\": [\"12008018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PKA signaling plays a major role in regulating both ChAT and VAChT mRNA levels in NG108-15 cells (H89, a PKA inhibitor, decreased both); PI3K inhibition (LY294002) had opposite effects on the two genes — decreasing ChAT mRNA while increasing VAChT mRNA — demonstrating that ChAT and VAChT can be differentially regulated despite their shared locus.\",\n      \"method\": \"Pharmacological inhibition of signaling kinases (H89, LY294002, PD98059) in NG108-15 cells; RT-PCR for mRNA levels; ChAT activity assays\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors tested with mRNA and activity readouts in a single lab study\",\n      \"pmids\": [\"12675145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"VAChT mRNA and protein upregulation with differentiating agents (retinoic acid, dexamethasone, dbcAMP) in NG108-15 cells does not always translate to increased VAChT protein, indicating post-transcriptional or post-translational regulation including deficient complex glycosylation that may affect targeting and/or stability of the VAChT membrane protein.\",\n      \"method\": \"RT-PCR, Western blot, ligand binding assays, transfection with luciferase reporter, glycosylation analysis in NG108-15 cells\",\n      \"journal\": \"Journal of physiology, Paris\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (mRNA, protein, binding, reporter) but single-lab study\",\n      \"pmids\": [\"11755784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In C. elegans, an unc-17/VAChT missense mutation (G347R in transmembrane domain 9) causing uncoordinated behavior is suppressed by a synaptobrevin/SNB-1 transmembrane domain mutation (I→D), suggesting a physical or functional association between VAChT and SNARE components at synaptic vesicles.\",\n      \"method\": \"Genetic epistasis/suppressor screen in C. elegans; behavioral analysis of double mutants\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis with allele-specific suppression, published in high-tier journal, mechanism-specific result\",\n      \"pmids\": [\"16604067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In C. elegans, the transmembrane protein SUP-1 physically associates with UNC-17/VAChT at synapses (demonstrated by bimolecular fluorescence complementation), and charge-complementary mutations in the transmembrane domains of SUP-1 (G84E) suppress the uncoordinated phenotype of UNC-17(G347R), suggesting electrostatic interactions between transmembrane domains modulate VAChT conformation and function.\",\n      \"method\": \"Genetic suppressor screen, bimolecular fluorescence complementation (BiFC), behavioral analysis in C. elegans\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BiFC proximity assay plus allele-specific genetic suppression, two orthogonal methods in one study\",\n      \"pmids\": [\"23051648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Overexpression of the transcription factor Lhx8 in SHSY5Y neuronal cells upregulates both ChAT and VAChT mRNA/protein expression and increases ACh release into culture medium, placing Lhx8 upstream of VAChT in the transcriptional control of cholinergic phenotype.\",\n      \"method\": \"Lentiviral Lhx8 overexpression in SHSY5Y cells; RT-PCR, Western blot, ACh release measurement\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — gain-of-function with mRNA, protein, and functional (ACh release) readouts, but single lab, single condition\",\n      \"pmids\": [\"24316404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAC transgenic mice overexpressing VAChT (with ~50 extra copies) show striatal VAChT protein overexpression and increased ACh release, leading to markedly enhanced amphetamine-induced stereotypies (confined sniffing and licking), demonstrating that VAChT-mediated increases in cholinergic tone directly exacerbate drug-induced repetitive behaviors.\",\n      \"method\": \"VAChT BAC transgenic mouse model; behavioral testing (amphetamine-induced stereotypy scoring); Western blot for striatal VAChT protein\",\n      \"journal\": \"Frontiers in neural circuits\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression with protein quantification and defined behavioral phenotype, replicated in Janickova et al. 2017\",\n      \"pmids\": [\"24904300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Biallelic loss-of-function variants in SLC18A3 (VAChT) cause presynaptic congenital myasthenic syndrome in humans, characterized by ptosis, ophthalmoplegia, fatigable weakness, apneic crises, and electrodecrement on repetitive stimulation — consistent with impaired ACh loading into presynaptic vesicles at the neuromuscular junction.\",\n      \"method\": \"Whole-exome sequencing; electrophysiological studies (repetitive nerve stimulation); clinical phenotyping\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetic loss-of-function validated by electrophysiology consistent with presynaptic mechanism, replicated across two unrelated families\",\n      \"pmids\": [\"27590285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VAChT overexpression in striatal cholinergic interneurons (ChAT-ChR2 BAC mice) dramatically reduces the number of cholinergic varicosities (−87%) while increasing their size (+177%) and alters VAChT trafficking along the somatodendritic and axonal arbor, demonstrating that VAChT expression levels regulate the morphology and intracellular trafficking of cholinergic terminals.\",\n      \"method\": \"Immunofluorescence quantification of VAChT-positive varicosities in transgenic mouse striatum; confocal microscopy; morphometric analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined morphological readout in genetic model with quantitative analysis, single lab\",\n      \"pmids\": [\"28628197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mice with ~65% knockdown of VAChT (VAChT-KDHOM) show reduced ACh release at neuromuscular junctions, causing muscle weakness with differential effects: fast-twitch EDL fibers atrophy while slow-twitch soleus fibers hypertrophy; altered expression of myogenesis markers (Pax7, MyoD, Myogenin), metabolic markers (PGC1-α), and protein degradation markers (Atrogin1, MuRF1) indicates distinct muscle adaptation to cholinergic deficits. These deficits are partially reversed by pyridostigmine.\",\n      \"method\": \"VAChT knockdown mouse model; muscle histology and morphometry; qRT-PCR for muscle-related genes; pyridostigmine pharmacological rescue\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with molecular and cellular phenotypic readouts plus pharmacological rescue, single lab\",\n      \"pmids\": [\"30003945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A homozygous nonsense variant in SLC18A3 [p.(Cys372Ter)] causes fetal akinesia deformation sequence (FADS) with arthrogryposis and edema, extending the disease spectrum beyond congenital myasthenic syndrome and suggesting complete loss of VAChT function is lethal prenatally — consistent with VAChT knockout mouse lethality.\",\n      \"method\": \"Exome sequencing; clinical and pathological phenotyping of affected fetuses\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — human genetics establishing null-allele phenotype, consistent with mouse knockout, but single family\",\n      \"pmids\": [\"31059209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Motoneuron-specific deletion of VAChT (Cre-loxP, mnVAChT-KD) in mice causes reduced ACh release, motoneuron soma shrinkage, innervated muscle atrophy, decreased muscle strength, hypoactivity, and kyphosis that worsen progressively — deficits partially rescued by cholinesterase inhibitor — establishing cell-autonomous requirement for VAChT in motoneuron function and neuromuscular junction integrity.\",\n      \"method\": \"Cre-loxP conditional knockout in motoneurons; immunofluorescence; muscle histology; grip strength and behavioral testing; pyridostigmine pharmacological rescue\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic loss-of-function with multiple orthogonal cellular and behavioral readouts plus pharmacological rescue in single rigorous study\",\n      \"pmids\": [\"33730374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SLC18A3/VAChT overexpression in renal cancer cells enhances uptake of acetylcholine, which activates the PKA/CREB signaling pathway to promote cell proliferation and invasive migration; SLC18A3 overexpression in mice bearing A498 renal cancer cells increases tumor growth and lung metastases.\",\n      \"method\": \"SLC18A3 overexpression in renal cancer cell lines; ACh uptake assays; PKA/CREB pathway analysis; xenograft mouse tumor model\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in vitro and in vivo with defined signaling pathway readouts, single lab\",\n      \"pmids\": [\"36225635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In cognitively normal older adults at risk for Alzheimer's disease, cholinergic neurons increase presynaptic VAChT protein levels when co-localized with tau (but not amyloid) pathology, and stronger VAChT responses are associated with cognitive resilience over a decade; forebrain-specific VAChT deletion in mice impairs cortical plasticity and hippocampal structural integrity, demonstrating VAChT-dependent cholinergic synaptic plasticity as a mechanism of resilience to tau pathology.\",\n      \"method\": \"Multi-tracer PET imaging in humans; forebrain-specific conditional VAChT knockout in mice; single-nucleus RNA sequencing; structural MRI\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — convergent human PET and mouse genetic KO with multiple orthogonal methods; preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"SLC18A3/VAChT is an integral membrane transporter located on synaptic vesicles of cholinergic neurons that actively loads acetylcholine into vesicles via an ATP-dependent, vesamicol-inhibitable mechanism; its gene resides within the first intron of ChAT and is co-regulated through shared RE1/NRSE silencer elements and PKA/PI3K signaling pathways; VAChT physically associates with SNARE components (synaptobrevin) and the transmembrane protein SUP-1 via transmembrane domain interactions that modulate its conformation and function; VAChT expression levels directly control the quantity of ACh available for release, with loss-of-function causing presynaptic congenital myasthenic syndrome or fetal akinesia in humans, and gain-of-function increasing cholinergic tone with consequences for striatal morphology, drug-induced behaviors, and cognitive resilience to tau pathology.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC18A3 (VAChT) is the vesicular acetylcholine transporter that defines the cholinergic phenotype of CNS and PNS neurons and loads acetylcholine into synaptic vesicles for release [#0, #1]. It localizes to synaptic vesicles in cholinergic nerve terminals, cell bodies, and dendrites, where it co-localizes with the ACh-synthesizing enzyme ChAT [#1], and it directly mediates ATP-dependent, vesamicol-inhibitable vesicular ACh uptake [#4]. The VAChT gene resides within the first intron of ChAT in a shared 'cholinergic gene locus' that permits coordinate transcriptional control through a common RE1/NRSE silencer engaged by REST/NRSF in non-neuronal cells [#2, #3], while PKA and PI3K signaling and upstream factors such as Lhx8 tune cholinergic gene output [#5, #9]. At the vesicle membrane VAChT functions in proximity to the SNARE protein synaptobrevin and the transmembrane protein SUP-1, whose transmembrane-domain interactions modulate VAChT conformation and activity [#7, #8]. VAChT expression levels set the quantity of releasable ACh and thereby govern neuromuscular and central cholinergic tone: biallelic loss-of-function variants cause presynaptic congenital myasthenic syndrome, and a null variant causes lethal fetal akinesia deformation sequence [#11, #14], whereas reduced or motoneuron-specific deletion produces neuromuscular junction failure, muscle atrophy, and weakness that is partially reversed by cholinesterase inhibition [#13, #15]. Conversely, VAChT overexpression raises cholinergic tone, remodels striatal cholinergic terminal morphology, and exacerbates drug-induced stereotypies [#10, #12].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that a single transporter transcript marks cholinergic neurons answered whether ACh vesicular storage has a dedicated, cell-type-defining carrier.\",\n      \"evidence\": \"In situ hybridization mapping of VAChT mRNA across rat CNS and PNS\",\n      \"pmids\": [\"7857778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mRNA distribution does not demonstrate transport activity\", \"subcellular localization not resolved by ISH\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Localizing VAChT protein to synaptic vesicles and confirming co-expression with ChAT established its position in the ACh release pathway.\",\n      \"evidence\": \"Immunohistochemistry with validated antisera, confocal microscopy, double-labeling with ChAT\",\n      \"pmids\": [\"9034903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"does not quantify transport function\", \"does not address regulation of expression\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping VAChT inside the first intron of ChAT revealed a shared cholinergic gene locus, framing how the two cholinergic genes might be co-regulated.\",\n      \"evidence\": \"Genomic cloning and structural analysis of the cholinergic locus\",\n      \"pmids\": [\"9782459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"functional consequence of shared locus not tested in this report\", \"regulatory elements not yet identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying an RE1/NRSE silencer bound by REST/NRSF explained how VAChT (and ChAT) are repressed in non-cholinergic cells, providing a molecular basis for coordinate cell-type-specific expression.\",\n      \"evidence\": \"Luciferase reporter transfection and EMSA for protein-DNA binding\",\n      \"pmids\": [\"10973977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"additional bound proteins beyond REST not fully defined\", \"in vivo requirement of the element not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that VAChT overexpression increases ATP-dependent, vesamicol-inhibitable ACh uptake confirmed VAChT as the direct mediator of vesicular ACh loading, while showing VAChT is not always the rate-limiting step for release.\",\n      \"evidence\": \"Stable VAChT transfection in PC12 cells with vesicular [3H]ACh/[14C]ACh uptake and vesamicol binding assays\",\n      \"pmids\": [\"12008018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism of transport coupling not resolved\", \"rate-limiting determinants of release not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing PKA and PI3K differentially regulate ChAT versus VAChT mRNA, and that differentiating agents act post-transcriptionally including via glycosylation, established that co-locus genes are nonetheless independently tunable and that VAChT protein levels are controlled beyond transcription.\",\n      \"evidence\": \"Kinase inhibitor pharmacology, RT-PCR, Western blot, and glycosylation analysis in NG108-15 cells\",\n      \"pmids\": [\"12675145\", \"11755784\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"signaling-to-promoter mechanism not mapped\", \"glycosylation effect on trafficking not directly demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Allele-specific suppression of an unc-17/VAChT transmembrane mutation by a synaptobrevin mutation provided genetic evidence for a functional association between VAChT and SNARE machinery at the vesicle.\",\n      \"evidence\": \"Genetic epistasis/suppressor screen and behavioral analysis in C. elegans\",\n      \"pmids\": [\"16604067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"physical interaction not shown biochemically\", \"interaction not confirmed in mammalian neurons\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating physical proximity of SUP-1 to UNC-17/VAChT and charge-complementary transmembrane suppression revealed that transmembrane-domain electrostatic interactions modulate VAChT conformation and function.\",\n      \"evidence\": \"BiFC proximity assay and allele-specific genetic suppression in C. elegans\",\n      \"pmids\": [\"23051648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mammalian SUP-1 ortholog and conservation not established\", \"structural basis of conformational modulation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placing Lhx8 upstream of VAChT in transcriptional control identified a transcription factor driving the cholinergic phenotype and ACh release.\",\n      \"evidence\": \"Lentiviral Lhx8 overexpression in SHSY5Y cells with RT-PCR, Western blot, and ACh release measurement\",\n      \"pmids\": [\"24316404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct promoter binding by Lhx8 not demonstrated\", \"single cell-line, single condition\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Gain-of-function studies linked VAChT levels to cholinergic tone and behavior, showing overexpression increases ACh release, drives amphetamine-induced stereotypies, and remodels striatal terminal morphology and trafficking.\",\n      \"evidence\": \"VAChT BAC transgenic and ChAT-ChR2 mice with behavioral scoring, Western blot, and varicosity morphometry\",\n      \"pmids\": [\"24904300\", \"28628197\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mechanism linking VAChT level to varicosity remodeling unresolved\", \"circuit-level cause of behavioral change not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying biallelic loss-of-function variants in human SLC18A3 established VAChT deficiency as a cause of presynaptic congenital myasthenic syndrome, confirming its physiological requirement for ACh loading at the neuromuscular junction.\",\n      \"evidence\": \"Whole-exome sequencing, repetitive nerve stimulation electrophysiology, and clinical phenotyping across families\",\n      \"pmids\": [\"27590285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"genotype-phenotype severity correlation not fully mapped\", \"molecular consequence of specific variants not assayed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A homozygous nonsense variant causing fetal akinesia extended the phenotypic spectrum and indicated that complete VAChT loss is prenatally lethal, consistent with knockout mouse lethality.\",\n      \"evidence\": \"Exome sequencing and clinical/pathological phenotyping of affected fetuses\",\n      \"pmids\": [\"31059209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"single family\", \"residual transporter function of hypomorphic alleles not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Quantitative loss-of-function and motoneuron-specific deletion established a cell-autonomous requirement for VAChT in neuromuscular junction integrity, with distinct fast- versus slow-twitch muscle adaptations and partial pharmacological rescue.\",\n      \"evidence\": \"VAChT knockdown and Cre-loxP conditional motoneuron knockout mice with histology, qRT-PCR, behavior, and pyridostigmine rescue\",\n      \"pmids\": [\"30003945\", \"33730374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"fiber-type-specific adaptation mechanism not fully defined\", \"long-term reversibility of deficits unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing VAChT-driven ACh uptake activates PKA/CREB to promote proliferation and metastasis implicated SLC18A3 in non-neuronal cholinergic signaling in renal cancer.\",\n      \"evidence\": \"SLC18A3 overexpression in renal cancer cells with ACh uptake assays, pathway analysis, and xenograft tumor model\",\n      \"pmids\": [\"36225635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"endogenous SLC18A3 dependence in tumors not tested by loss-of-function\", \"source of ACh in tumor context unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Convergent human PET and mouse genetic data tied VAChT-dependent presynaptic plasticity to cognitive resilience against tau pathology, framing cholinergic capacity as a protective mechanism.\",\n      \"evidence\": \"Multi-tracer PET in older adults, forebrain-specific conditional VAChT knockout mice, snRNA-seq, and structural MRI (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"preprint not yet peer-reviewed\", \"causal direction between VAChT upregulation and resilience not established in humans\", \"molecular trigger for tau-associated VAChT increase unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The atomic structure of VAChT and the transport/coupling mechanism by which it loads ACh into vesicles remain undefined in the available corpus.\",\n      \"evidence\": \"No structural or reconstituted mechanistic study present in the timeline\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no high-resolution structure\", \"ion/proton coupling stoichiometry not characterized\", \"vesamicol binding site not mapped structurally\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [4, 0, 1]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SNB-1\", \"SUP-1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}